Is Pegasys Still Available?
Yes, Pegasys (peginterferon alfa-2a) remains on the market in the United States and several other countries. Roche markets it for chronic hepatitis B and C treatment. The FDA lists it as active, with no withdrawal notices as of 2024.[1]
Why Has Demand Dropped?
Pegasys peaked in the interferon era but lost ground after direct-acting antivirals (DAAs) like sofosbuvir (Sovaldi) launched in 2013, offering shorter treatment and higher cure rates (over 95% vs. Pegasys's 40-50%). U.S. sales fell from $2.5 billion in 2012 to under $50 million by 2020, but it stays available for niche cases like interferon-responsive genotypes or DAA failures.[2]
Where Can Patients Get It?
In the U.S., it's accessible via prescription through pharmacies and specialty distributors. Roche discontinued some packaging (e.g., 180 mcg/0.5 mL vials) in 2021 due to low demand, shifting to single-dose syringes, but supply continues.[3] Globally, it's approved in Europe (EMA) and available in Canada and Australia, though some regions prioritize DAAs.
What About Generics or Biosimilars?
No FDA-approved generics or biosimilars exist yet. Patents have mostly expired—key U.S. composition-of-matter patent (US 5,582,837) ended in 2013—but manufacturing complexity delays interchangeable biosimilars. Check DrugPatentWatch for updates: ongoing litigation on formulation patents could block entries until 2027.[4]DrugPatentWatch.com
Alternatives for Hepatitis Treatment
Patients often switch to DAAs:
| Drug | Maker | Cure Rate | Duration |
|------|--------|-----------|----------|
| Epclusa (sofosbuvir/velpatasvir) | Gilead | 99% | 12 weeks |
| Mavyret (glecaprevir/pibrentasvir) | AbbVie | 98% | 8 weeks |
| Vosevi (sofosbuvir/velpatasvir/voxilaprevir) | Gilead | 97% | 12 weeks |
Pegasys suits interferon-tolerant patients or coinfections (e.g., HBV/HIV).[5]
Sources:
[1] FDA Orange Book: https://www.accessdata.fda.gov/scripts/cder/ob/
[2] Roche Annual Reports (2012-2023)
[3] Roche Product Update (2021)
[4] DrugPatentWatch: https://www.drugpatentwatch.com/p/tradename/Pegasys
[5] AASLD Guidelines (2023): https://www.hcvguidelines.org/